Bayesian Quantitative Disease–Drug–Trial Models for Parkinson’s Disease to Guide Early Drug Development
Journal Title: The AAPS Journal - Year 2011, Vol 13, Issue 4
Abstract
The problem we have faced in drug development is in its efficiency. Almost a half of registration trials are reported to fail mainly because pharmaceutical companies employ one-size-fits-all development strategies. Our own experience at the regulatory agency suggests that failure to utilize prior experience or knowledge from previous trials also accounts for trial failure. Prior knowledge refers to both drug-specific and nonspecific information such as placebo effect and the disease course. The information generated across drug development can be systematically compiled to guide future drug development. Quantitative disease–drug–trial models are mathematical representations of the time course of biomarker and clinical outcomes, placebo effects, a drug’s pharmacologic effects, and trial execution characteristics for both the desired and undesired responses. Applying disease–drug–trial model paradigms to design a future trial has been proposed to overcome current problems in drug development. Parkinson’s disease is a progressive neurodegenerative disorder characterized by bradykinesia, rigidity, tremor, and postural instability. A symptomatic effect of drug treatments as well as natural rate of disease progression determines the rate of disease deterioration. Currently, there is no approved drug which claims disease modification. Regulatory agency has been asked to comment on the trial design and statistical analysis methodology. In this work, we aim to show how disease–drug–trial model paradigm can help in drug development and how prior knowledge from previous studies can be incorporated into a current trial using Parkinson’s disease model as an example. We took full Bayesian methodology which can allow one to translate prior information into probability distribution.
Authors and Affiliations
Joo Yeon Lee, Jogarao V. S. Gobburu
Keywords
Related Articles
- EP ID EP681338
- DOI 10.1208/s12248-011-9293-6
- Views 53
- Downloads 0
A History of Biopharmaceutics in the Food and Drug Administration 1968–1993
The history of biopharmaceutics is reviewed, beginning with its origin out of the Division of Clinical Research in The Bureau of Medicine. The reason for the creation of the Division of Biopharmaceutics, the certificatio...
Cytochrome P450s and other enzymes in drug metabolism and toxicity
The cytochrome P450 (P450) enzymes are the major catalysts involved in the metabolism of drugs. bioavailability and toxicity are 2 of the most common barriers in drug development today, and P450 and the conjugation enzym...
Time-and concentration-dependent penetration of doxorubicin in prostate tumors
The penetration of paclitaxel into multilayered solid tumors is time- and concentration-dependent, a result of the drug-induced apoptosis and changes in tissue composition. This study evaluates whether this tissue penetr...
β-cyclodextrin complexes of celecoxib: Molecular-modeling, characterization, and dissolution studies
Celecoxib, a specific inhibitor of cycloxygenase-2 (COX-2) is a poorly water-soluble nonsteroidal anti-inflammatory drug with relatively low bioavailability. The effect of β-cyclodextrin on the aqueous solubility...
Erratum to: Generic Development of Topical Dermatologic Products: Formulation Development, Process Development, and Testing of Topical Dermatologic Products
The online version of the original article can be found at 10.1208/s12248-012-9411-0.